Body of evidence and approaches applied in the clinical development programme of fixed‐dose combinations in the European Union from 2010 to 2016
Open Access
- 11 May 2019
- journal article
- research article
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 85 (8) , 1829-1840
Abstract
Aims: To provide insights into the clinical development pathway for fixed‐dose combinations (FDCs), to consider strategies, and to elucidate the path to approval by assessing the body of evidence, as summarized in the European Public Assessment Reports.Methods: The main resource was the European Public Assessment Reports for 36 FDCs, which included 239 clinical trials with 157 514 patients. The analyses focused on how prior knowledge of the active substances or combination, use of pharmacokinetic–pharmacodynamic modelling, and clinical trial design choice impact the size and strategy of the clinical development programme.Results: FDC products primarily comprised 2 previously approved components (21/36, 71%) and had only 1 approved combination (21/36, 71%). Utilizing previously approved active substances resulted in fewer clinical trials, arms and patients, but FDC doses studied in the clinical development programme. Furthermore, dose‐finding trials were performed for less than half of FDCs consisting of 2 previously approved active substances. The standard approach to demonstrate contribution of active substances was through a factorial or single combination study. Finally, the use of pharmacokinetic modelling showed a significant decrease in the number of FDC doses studied.Conclusions: The field of FDCs seems to be on the rise, utilizing new molecular entities, prior knowledge and re‐profiling drugs. However, a way to move FDC development forward might be through new regulatory and scientific paradigms, in which it is encouraged to utilize model‐based approaches to develop FDCs with multiple dose levels and dose ratios for exposure‐based treatment that will enable personalization.Keywords
Funding Information
- Novo Nordisk
This publication has 20 references indexed in Scilit:
- BRAID: A Unifying Paradigm for the Analysis of Combined Drug ActionScientific Reports, 2016
- Good Practices in Model‐Informed Drug Discovery and Development: Practice, Application, and DocumentationCPT: Pharmacometrics & Systems Pharmacology, 2015
- An Analysis of the Fixed-Dose Combinations Authorized by the European Union, 2009–2014: A Focus on Benefit-Risk and Clinical Development ConditionsTherapeutic Innovation & Regulatory Science, 2015
- Analysis of drug combinations: current methodological landscapePharmacology Research & Perspectives, 2015
- Model‐based clinical drug development in the past, present and future: a commentaryBritish Journal of Clinical Pharmacology, 2014
- Calculated treatmentNature, 2013
- Combination approaches to combat multidrug-resistant bacteriaTrends in Biotechnology, 2013
- Evaluation of false positive rate based on exposure–response analyses for two compounds in fixed-dose combination productsJournal of Pharmacokinetics and Pharmacodynamics, 2011
- Fixed dose drug combinations (FDCs): rational or irrational: a view pointBritish Journal of Clinical Pharmacology, 2008
- A robustness-based approach to systems-oriented drug designNature Reviews Drug Discovery, 2007